Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2012 | short review

Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology

verfasst von: Bernhard Schuknecht, MD, Krisztina Baráth, MD, Silvia Hofer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Novel therapies of central nervous system (CNS) malignancies have evoked the demand to increasingly integrate dedicated imaging techniques into the diagnostic work-up and treatment evaluation in neuro-oncology. In primary and secondary malignancies of the CNS, advanced neuroimaging techniques enable non-invasive assessment of tissue microstructure, cellular and vascular proliferation and capillary permeability. Furthermore, eloquent cortical areas in the vicinity of tumours and the course of white matter pathways are rendered visible to facilitate surgical therapy.
The armamentarium of magnetic resonance (MR) imaging techniques includes diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), diffusion-tensor imaging (DTI), functional MRI (f-MRI) and MR spectroscopy (MRS). Computed tomography perfusion (perfusion CT) may serve as an alternative to magnetic resonance perfusion (perfusion MR). These new imaging techniques lend support to distinguish the primary brain neoplasms from the secondary brain neoplasms, aid in grading of gliomas, delineate infiltration beyond visible boundaries on contrast-enhanced images and thus support guidance for biopsies and surgical resection. Surveillance and treatment monitoring of neoplasms may shift from almost exclusive reliance on contrast enhancement to an imaging approach that combines traditional morphology with advanced “functional” techniques.
Validation of these new developments is ongoing based on the observations in clinical neuro-oncology, radiation oncology, histopathology and neurosurgery. Application of advanced imaging protocols may promise to improve diagnosis, to stratify patients to an increasing diversity of treatment options and potentially individualise therapy.
Vorheriger Artikel Carcinomatous meningitis
Nächster Artikel Drug therapy for recurrent, progressive, atypical, and malignant meningiomas
Fußnoten
1
Figure legends (same patient in Figs. 1, 2, 3, 4, 5 and 6) exemplifying preoperative assessment of a patient with mixed oligodendroglioma.
 
Literatur
1.
Hofer S, Lassmann AB. Molecular markers in gliomas: impact for the clinician. Target Oncol. 2010;5:201–10.PubMedCrossRef
2.
Tabatabai G, Stupp R, Van Den Bent MJ, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. (2010) 120:585–92.PubMedCrossRef
3.
Carillo JA, Lai A, Nghiemphu PL. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012. doi:10.3174/ajnr.A2950.
4.
Kim JW, Park CK, Park SH, et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry. 2011;82:224–7.PubMedCrossRef
5.
Goze C, Rigau V, Gibert L, et al. Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol. 2009;91:1–5.PubMedCrossRef
6.
Drabycz S, Roldan G, de Robles P, et al. An analysis of image texture, tumorlocation, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010;49:1398–405.PubMedCrossRef
7.
Wen P, Macdonald DR, Reardon DAR, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72PubMedCrossRef
8.
Ellingson BM, Mark G, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011;102:95–103.
9.
Arvinda HR, Kesavadas C, Sarma PS, et al. Glioma grading:sensitivity, specificity, positive and negative predictive values of diff usion and perfusion imaging. J Neurooncol. 2009;94:87–96.PubMedCrossRef
10.
Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol. 2011;32:1301–6.PubMedCrossRef
11.
Chiang IC, Kuo Y-T, Luc-Y, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imaging. Neuroradiology. 2004;46:619–27.
12.
Barajas RF Jr., Rubenstein JL, Chang JS, et al. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2010;31:60–6.
13.
Pope WB, Kim HJ, Huo J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182–9.PubMedCrossRef
14.
Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion maps an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387–94.PubMedCrossRef
15.
Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011; 32:882–9.PubMedCrossRef
16.
Mong S, Ellingson BM, Nghiemphu PL, et al. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol. 2012. doi:10.3174/ajnr.A3053.
17.
Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume andvascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004; 25: 746–5.PubMed
18.
Law M, Oh S, Babb JS, et al. Low grade gliomas: dynamic susceptibility weighted contrast enhanced perfusion MR imaging prediction of patient clinical response. Radiology. 2006; 238:658–67.PubMedCrossRef
19.
Maia ACM, Malheiros SMF, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005;26:777–83.PubMed
20.
Tykocinski ES, Grant RA, Kapoor GS, et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro-Oncol. 2012;14:613–23.PubMedCrossRef
21.
Essig M, Anzalone N, Combs SE, et al. MR Imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol. 2012;33:803–17.PubMedCrossRef
22.
Haldorsen IS, Espeland A, Larsson E.-M, et al. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32:984–92.PubMedCrossRef
23.
Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low grade gliomas: do changes in rCBV measurements at longitudinal perfusion weighted MR imaging predict malignant transformation? Radiology. 2008;247:170–8.PubMedCrossRef
24.
Tsien C, Galbán CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28:2293–9.PubMedCrossRef
25.
Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging—pilot study. Radiology, 2010;255:622–8.PubMedCrossRef
26.
Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. 2010;256:575–84.PubMedCrossRef
27.
Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2008;30:552–8.PubMedCrossRef
28.
Kong D-S, Kim ST, Kim E-H, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and lxygen-6-Methylguanine-DNA Methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–7.PubMedCrossRef
29.
Stadlbauer A, Ganslandt O, Buslei R, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology. 2006;240:803–10.PubMedCrossRef
30.
Inoue T, Ogasawara K, Beppu T, et al. Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas. Clin Neurol Neurosurg. 2005;107:174–80.PubMedCrossRef
31.
Price SJ Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor Imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006;27:1969–74.PubMed
32.
Price SJ, Jena R, Burnet NG, et al. Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol. 2007;17:1675–87.PubMedCrossRef
33.
Saksena S, Jain R, Narang J, et al. Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging. 2010;32:788–95.PubMedCrossRef
34.
Sundgren PC, Fan X, Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast enhancing lesions. Magn Reson Imaging. 2006;24:1131–42.PubMedCrossRef
35.
Bello L, Gambini A, Castellano A, et al. Motor and language DTI fiber tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. NeuroImage. 2008;39:369–82.PubMedCrossRef
36.
Partovi S, Jacobi B, Rapps N, et al. Clinical standardized fMRI reveals altered language lateralization in brain tumor patients. AJNR Am J Neuroradiol. doi:10.3174/ajnr.A3137.
37.
Roux FE, Boulanouar K, Ibarrola D, et al. Functional MRI and intraoperative brain mapping to evaluate brain plasticity in patients with brain tumours and hemiparesis. J Neurol Neurosurg Psychiatry. 2000;69(4):453–63.
38.
Desmurget M, Bonnetblanc F, Duffau H. Contrasting acute and slow-growing lesions: a new door to brain plasticity. Brain. 2007, 130, 898–914.PubMedCrossRef
39.
Roessler K, Donat M, Lanzenberger R, et al. Evaluation of preoperative high magnetic field motor functional MRI (3 Tesla) in glioma patients by navigated electrocortical stimulation and postoperative outcome. J Neurol Neurosurg Psychiatry. 2005;76:1152–7.PubMedCrossRef
40.
Hattingen E, Delic O, Franz K, et al. 1H MRSI and progression-free survival in patients with WHO grades II and III gliomas. Neurol Res. 2010; 32: 593–602.PubMedCrossRef
41.
Law M, Yang, S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989–98.PubMed
42.
Elias A, Carlos RC, Smith E, et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol. 2011;18:1101–8.PubMedCrossRef
43.
Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonancespectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol. 2006;76:185–91.PubMedCrossRef
44.
45.
Zeng QS, Li CF, Zhang K, et al. Multivoxel 3D proton MR spectroscopy inthe distinction of recurrent glioma from radiation injury. J Neurooncol. 2007;84:63–9.PubMedCrossRef
46.
Jeon JY, Kovanlikaya I, Boockvar JA, et al. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton magnetic resonance spectroscopic imaging study. AJNR Am J Neuroradiol. 2012 May 10. doi:0.3174/ajnr.A3091.
Metadaten
Titel
Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology
verfasst von
Bernhard Schuknecht, MD
Krisztina Baráth, MD
Silvia Hofer, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0046-8

Weitere Artikel der Ausgabe 3/2012

Sorafenib in thyroid cancer—a retrospective case series

  • case report

News from the Neuro-Oncology front

  • editorial

Current treatment of low grade gliomas

  • Open Access
  • review

ASH 2011—current developments in AML

  • short review

Carcinomatous meningitis

  • short review

Update on molecular and genetic alterations in adult medulloblastoma

  • Open Access
  • short review